 |
|
|
| |
In Vitro Forgiveness of INSTI-Containing Regimens at Drug Concentrations
Simulating Variable Adherence
|
| |
| |
IDWeek 2021 Sept 29-Oct 3
Rima K. Acosta, Michelle L. D'Antoni, Andrew Mulato, Stephen R. Yant, Tomas Cihlar, Kirsten White - Gilead Sciences, Inc., Foster City, CA
References: 1. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents With HIV; 8/16/21; 2. EACS Guidelines Version 10.0 November 2019; 3. Mulato A, et al. J Acquir Immune Defic Syndr 2021;86:369-77; 4. Biktarvy [package insert]. Foster City, CA: Gilead Sciences, Inc.; 9/21; 5. Dovato [package insert]. Research Triangle Park, NC: ViiV Healthcare; 3/21; 6. Juluca [package insert]. Research Triangle Park, NC: ViiV Healthcare; 3/21; 7. Tivicay [package insert]. Research Triangle Park, NC: ViiV Healthcare; 3/21; 8. Tsiang M, et al. Antimicrob Agents Chemother 2016;60:7086-97; 9. European Medicines Agency. CHMP assessment report: Edurant; 9/22/11; 10. Dickinson L, et al. Antimicrob Agents Chemother 2015;5910:6080-6; 11. Else LJ, et al. Antimicrob Agents Chemother 2011;56:1427-33;
12. Yuen GJ, et al. Antimicrob Agents Chemother 2004;48:176-82; 13. Callebaut C, et al. PLoS One 2017;12:e0169948; 14. Custodio JM, et al. Antimicrob Agents Chemother 2016;60:5235-4. Acknowledgments: The authors thank Alex Thielen and Martin Daeumer at Seq-IT, and Ross Martin and Silvia Chang at Gilead for deep-sequence analyses. This study was funded by Gilead.
|
| |
|
|
|
|
|
